VIDA: Advancing Respiratory Care through Intelligence

VIDA: Advancing Respiratory Care through Intelligence

Follow VIDA on :

Susan A Wood, PhD., President & CEO, VIDASusan A Wood, PhD., President & CEO, VIDA
Over the past several decades, the negative impact of respiratory disease has continued to grow in both prevalence and cost of care. In more recent events, the coronavirus pandemic has shone a spotlight on the potential for extreme burden to patients and the healthcare system in managing complex respiratory conditions. While we have historically lacked the kind of accurate data that would enable early detection and effective treatment planning, the pace of innovation in technology now finds us equipped with tools that can have a transformative impact on patient care at the individual and system-wide levels.

VIDA, with its deep history in respiratory care and clinically-validated approach to AI imaging analysis, is at the vanguard of supporting physicians in tackling patient care challenges. “We have played a key role for over a decade in academic and industry clinical trials and are now applying leading expertise to support care delivery in health systems,” says Susan Wood, PhD., President and CEO of the company. VIDA provides evidence-based analysis that can aid in early detection, evaluation, and/or treatment of respiratory diseases, including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), asthma and now COVID-19.

VIDA’s AI-based lung analysis solution, LungPrint, takes a unique approach to evaluating patients with or at-risk of lung diseases. Leveraging comprehensive data from patient chest CTs, LungPrint is able to provide radiologists with a powerful blend of qualitative and quantitative reports that decrease highly complex chest CT read times by 35 percent, highlight areas that may require additional physician attention and offer rapid secondary validation of findings. The solution integrates with existing radiology workflows and yields actionable insights for both radiologists and pulmonologists.


We are a clinical AI company that is playing a key role in a number of academic and industry validation trials as well as care delivery in health systems

“As LungPrint becomes part of the standard of care, we have the opportunity to support earlier detection of COPD and ILD, to provide precision reports for personalized treatment selection based on the presence of unique biomarkers and to monitor patients longitudinally for disease management,” says Susan. This helps to achieve the value-based care triple aim of improving the patient experience, enhancing quality of care and driving positive outcomes at lower overall cost.

Some of the cost burden to the healthcare system has been driven by an inability to target the right drug to the right patient at the right time. Developing a drug from discovery to commercialization is a long and complex undertaking. Respiratory diseases bring an additional set of challenges to the process. “Because the clinical endpoints are generalized rather than being objective and repeatable, it is quite difficult to understand if a drug is working,” says Susan. VIDA supports clinical trials with services ranging from pre-clinical imaging consulting to data analysis and interpretation. “In our clinical trials, we use imaging-based biomarkers and depend on fewer subjects, and as a result, we accelerate the time to market of the drug,” she adds. More importantly, clients can easily understand if a particular molecule is likely to deliver the expected results in the early stages of drug development. This can help research teams define precise endpoints during clinical trials and potentially contribute to development of more personalized drugs. VIDA’s quality-controlled imaging service has been used in over 60 academic and industry clinical trials across 30 countries to date. These services are delivered from VIDA’s specialized core lab, operated with an ISO-13485 certified quality system.

In one VIDA case study of clinical application, a patient was diagnosed with severe asthma and treated accordingly but saw no improvement to his health. Revisiting the chest CT with LungPrint, the radiologist found evidence suggesting the patient had an alpha-1 antitrypsin deficiency that had led to COPD. Now empowered with more precise and accurate information, the treating physician ran a genetic test and re-evaluated the findings, then adjusted patient treatment to focus on the accurate underlying condition.

Share this Article:
VIDA

Company
VIDA

Headquarters
Coralville, IA

Management
Susan A Wood, PhD., President & CEO

Description
VIDA, with its deep history in respiratory care and clinically-validated approach to AI imaging analysis, is at the vanguard of supporting physicians in tackling patient care challenges. The company provides evidence-based analysis that can aid in early detection, evaluation, and/or treatment of respiratory diseases, including chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), asthma and now COVID-19. VIDA’s AI-based lung analysis solution, LungPrint, takes a unique approach to evaluating patients with or at-risk of lung diseases. Using the company’s offerings, organizations can easily understand if a particular molecule is likely to deliver the expected results in the early stages of drug development

VIDA News

VIDA Completes Second Close Of Round C Financing

$2M Second Close from Strategic Partners Completes $13M C Round to Advance AI-Powered Respiratory Solutions

CORALVILLE, Iowa - ,VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, received $2M from OSF Ventures, the corporate investment arm of OSF HealthCare, as a second close of its C round funding. This investment augments an $11M investment round last month led by First Analysis Corporation and will further fuel development and commercialization of VIDA's innovative solutions to impact patient care for both traditional respiratory diseases as well as emergent COVID-19 conditions.

"OSF is an ideal strategic partner for VIDA. Through both capital and access to clinic leaders, OSF is a catalyst in expanding the footprint of our FDA-approved, AI-powered imaging solutions in this growing market," said Susan A. Wood, Ph.D. and CEO for VIDA. "Providing access to analysis like LungPrint has never been more important, given the global COVID-19 pandemic on top of an already growing trend of chronic respiratory and lung diseases."

"We invest in leading-edge solutions that make an immediate impact for OSF Healthcare's care teams and patients," said Garrett Vygantas, MD, Managing Director at OSF Ventures. "VIDA's LungPrint solution helps radiologists and pulmonologists gain valuable insight into each patient's unique condition, which determines the appropriate treatment plan. We see real value for this new technology to help treat patients with COPD, lung cancer and other pulmonary diseases -and we anticipate LungPrint will help us in the future manage new populations experiencing COVID-19 and determine appropriate follow up and long-term care."

LungPrint® is an AI-powered suite of products and services used to uniquely profile and manage the patient with, or at-risk of respiratory and lung diseases. LungPrint provides clinically validated imaging analysis to healthcare providers and clinical trial partners to obtain a more precise, personalized profile of respiratory and lung health. LungPrint is clinically cleared in the US (FDA 510(k)), EU (CE), Australia (TGA) & Canada (CMDCAS).